SLN

Silence Therapeutics plc

BS score 24.0LOWPHASE2 · mkt cap $274.0M · rev ttm $559.0K

drug hypothesis

SLN124 modulates Unknown - not disclosed in provided materials to treat Healthy Volunteers (Phase 1 safety/tolerability study - no therapeutic indication yet).

moa:Unknown - not disclosed in provided materials

score breakdown

trial design20

base rate disconnect10

language red flags60

composite24.0

valuation analysis

market cap$274.0M

revenue ttm$559.0K

phasePHASE2

historical base rate15%

disconnect ratio0.4x

lead trialNCT05537571

meta

cik0001479615

first discovered2026-04-09

last updated2026-04-10

statusACTIVE

llm model—

extracted at2026-04-10

trial design

Phase 1, randomized, double-blind, placebo-controlled study in 24 healthy volunteers. Secondary endpoints include pharmacokinetic parameters: Cmax, AUC, and apparent total clearance (CL/F) after subcutaneous injection.

primary endpoint:Incidence of treatment-emergent adverse events (8 weeks)

claimed differentiation

Not provided - no differentiation claims in available materials

language red flags

Insufficient data provided to assess claims - filing content extremely limited (shows only '4' as business section)
No target, mechanism, or preclinical evidence disclosed in available materials
No differentiation claims or risk factors stated in provided SEC excerpt